177 related articles for article (PubMed ID: 36823653)
21. Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.
Wang H; Schabath MB; Liu Y; Han Y; Li Q; Gillies RJ; Ye Z
Eur J Radiol; 2016 Nov; 85(11):1934-1940. PubMed ID: 27776643
[TBL] [Abstract][Full Text] [Related]
22. The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients.
Song Z; Liu T; Shi L; Yu Z; Shen Q; Xu M; Huang Z; Cai Z; Wang W; Xu C; Sun J; Chen M
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):361-371. PubMed ID: 32794105
[TBL] [Abstract][Full Text] [Related]
23. Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database.
Matsuura Y; Mun M; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H;
J Surg Oncol; 2023 Oct; 128(5):916-924. PubMed ID: 37403534
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.
Kim TJ; Park CK; Yeo CD; Park K; Rhee CK; Kim J; Kim SJ; Lee SH; Lee KY; Yoon HK
J Surg Oncol; 2014 Sep; 110(3):245-51. PubMed ID: 24888607
[TBL] [Abstract][Full Text] [Related]
25. [Relationship between EGFR, ALK Gene Mutation and Imaging
and Pathological Features in Invasive Lung Adenocarcinoma].
Yang H; Liu Z; Wang H; Chen L; Wang J; Wen W; Xu X; Zhu Q
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):147-155. PubMed ID: 35340157
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.
Chang WC; Kim HK; Shin BK
Oncol Rep; 2020 Jan; 43(1):218-228. PubMed ID: 31746406
[TBL] [Abstract][Full Text] [Related]
27. ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria.
Djambazov SN; Vekov TY; Mekov EV; Slavchev GS; Petkov RE; Kostadinov DT; Konteva LT
Folia Med (Plovdiv); 2018 Sep; 60(3):397-401. PubMed ID: 30355843
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.
Zhou JY; Zheng J; Yu ZF; Xiao WB; Zhao J; Sun K; Wang B; Chen X; Jiang LN; Ding W; Zhou JY
Eur Radiol; 2015 May; 25(5):1257-66. PubMed ID: 25577516
[TBL] [Abstract][Full Text] [Related]
29. Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas.
Wang H; Wang Y; Zhang H; Han Y; Li Q; Ye Z
Clin Radiol; 2020 Jul; 75(7):562.e21-562.e29. PubMed ID: 32307109
[TBL] [Abstract][Full Text] [Related]
30. Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa.
Jazieh AR; Gaafar R; Errihani H; Jaafar H; Al Dayel F; Bahnassy AA; El Kadi H; Abdallah MM; Zaatari G
JCO Glob Oncol; 2021 Sep; 7():1556-1563. PubMed ID: 34788123
[TBL] [Abstract][Full Text] [Related]
31. Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study.
Tan X; Li Y; Wang S; Xia H; Meng R; Xu J; Duan Y; Li Y; Yang G; Ma Y; Jin Y
Respir Res; 2022 May; 23(1):132. PubMed ID: 35624472
[TBL] [Abstract][Full Text] [Related]
32. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics].
Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J
Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670
[TBL] [Abstract][Full Text] [Related]
33. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.
Zhang NN; Liu YT; Ma L; Wang L; Hao XZ; Yuan Z; Lin DM; Li D; Zhou YJ; Lin H; Han XH; Sun Y; Shi Y
PLoS One; 2014; 9(1):e84501. PubMed ID: 24404167
[TBL] [Abstract][Full Text] [Related]
34. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
[TBL] [Abstract][Full Text] [Related]
35. Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Thorac Cancer; 2021 Sep; 12(17):2388-2399. PubMed ID: 34288491
[TBL] [Abstract][Full Text] [Related]
36. Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder.
He CH; Shih JF; Lai SL; Chen YM
J Chin Med Assoc; 2020 May; 83(5):461-465. PubMed ID: 32221155
[TBL] [Abstract][Full Text] [Related]
37. Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma.
Han X; Fan J; Li Y; Cao Y; Gu J; Jia X; Wang Y; Shi H
Sci Rep; 2021 Mar; 11(1):5679. PubMed ID: 33707479
[TBL] [Abstract][Full Text] [Related]
38. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
[TBL] [Abstract][Full Text] [Related]
39. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
40. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
